Chiron's Conservative Cash Play
Two years after selling off its diagnostics business, Chiron has finally decided how to spend some of the money: it bought Pathogenesis for about $700 million. The move brings one small marketed product, and complementary research capacity that promises mostly longer-term benefit for Chiron's interests in infectious diseases. Analysts and investors aren't thrilled by the conservative move, but they're not bailing out either.
You may also be interested in...
Investors are buying into Corus, which is betting that it can find value in anti-infectives and respiratory products that others discarded because of problematic clinical trials.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.